Stocks · News reference
Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est
Xtant Medical Hldgs (AMEX:XTNT) lowers FY2026 sales outlook from $101.000 million-$105.000 million to $99.000 million-$103.000 million vs $102.058 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LUCID CAPITAL MARKETS Initiates Coverage On Xtant Medical Holdings with Buy Rating, Announces Price Target of $1
Xtant Medical Enters Exclusive Partnership With Henry Schein's Biohorizons To Distribute The Company's Allogeneic Growth Factor Technology Under The Prolifica Private Brand
The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and Canada, expanding
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings